Observational study of Asciminib in patients with Chronic Myeloid Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and effectiveness of Asciminib in real-world clinical settings for patients with Chronic Myeloid Leukemia (CML) in Korea. It will enroll adult patients diagnosed with Ph+ CP-CML who are prescribed Asciminib at the discretion of their physicians. The study will follow these patients for two years after the market launch of the medication, allowing for a comprehensive evaluation of treatment outcomes. The dosage and duration of treatment will be determined by the investigator based on the prescribing information.

Why it matters

Who can join: the full rules

Inclusion criteria

1. Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
2. Patients who are willing to provide written informed consent prior to study enrollment

Exclusion criteria

1. Patients with contraindication according to locally approved label of Scemblix®
2. Patients who receive or are going to receive any investigational medicine during the observation period

Where it's running

• Novartis Investigative Site
  Wŏnju, Gangwon-do, South Korea Recruiting
• Novartis Investigative Site
  Anyang-si, Gyeonggi-do, South Korea Recruiting
• Novartis Investigative Site
  Bucheon-si, Gyeonggi-do, South Korea Recruiting
• Novartis Investigative Site
  Uijeongbu-si, Gyeonggi-do, South Korea Recruiting
• Novartis Investigative Site
  Gyeonggi-do, Korea, South Korea Recruiting
• Novartis Investigative Site
  Incheon, Korea, South Korea Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Potential of asciminib in early chronic‑phase CML

  This trial will see if asciminib alone, or asciminib plus nilotinib, helps adults newly diagnosed with chronic‑phase, BCR‑ABL–positive CML reach deep molecular responses and remain off treatment.

  Recruiting at 11 sites Phase 2 Gruppo Italiano Malattie EMatologiche dell'Adulto · Barcelona and 10 other locations · NCT06409936

• Evaluating asciminib for newly diagnosed chronic myeloid leukemia patients

  This study is testing a new drug called asciminib to see if it helps people with newly diagnosed chronic myeloid leukemia feel better and achieve a good response to treatment after a year.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06236724

• Asciminib for chronic phase CML with T315I mutation

  This study tests asciminib 200 mg twice daily in adults with chronic phase CML and a T315I mutation after stem cell transplant to see if it helps control leukemia.

  Recruiting at 5 sites Phase 2 University of Jena · Aachen and 9 other locations · NCT07789574

• Asciminib for Ph+ CML-CP in Germany: real-world patient experiences

  This real-world study tests how asciminib performs in adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, including those newly diagnosed or after one prior TKI.

  Recruiting at 74 sites Novartis · Baden-Baden, Baden-Wurttemberg and 73 other locations · NCT07549516

• Asciminib in children and young adults with relapsed or refractory Ph+ or ABL-class Ph-like ALL

  This study tests asciminib in kids and young adults with relapsed or refractory Philadelphia-positive or ABL-class Ph-like ALL to see if it is safe and helps treat the leukemia.

  Recruiting at 4 sites Phase 1/2 Novartis · Sydney, New South Wales and 3 other locations · NCT07387926

• Scemblix (asciminib) for newly diagnosed chronic-phase CML in China

  This project will try asciminib (Scemblix) in adults newly diagnosed with chronic-phase CML to see if it controls the disease and is safe.

  Recruiting Novartis · Wuhan, Hubei · NCT07375355

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.